Provided by Tiger Trade Technology Pte. Ltd.

GENSCRIPT BIO

34.440
+1.0803.24%
Volume:34.78M
Turnover:1.19B
Market Cap:75.70B
PE:-17.87
High:34.760
Open:33.200
Low:32.500
Close:33.360
52wk High:35.220
52wk Low:10.360
Shares:2.20B
HK Float Shares:2.20B
Volume Ratio:0.51
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.927
ROE:-15.33%
ROA:1.54%
PB:2.48
PE(LYR):-17.87
PS:11.43

Loading ...

GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC

Bulletin Express
·
May 12

A Look At Genscript Biotech (SEHK:1548) Valuation After Recent Share Price Momentum

Simply Wall St.
·
May 09

Genscript Biotech marginally expands issued share base after option exercise

Bulletin Express
·
May 06

Is It Time To Reassess Genscript Biotech (SEHK:1548) After Its Recent Share Price Recovery?

Simply Wall St.
·
Apr 25

Genscript Biotech Governance Reset Puts Shareholder Rights Under Fresh Focus

Simply Wall St.
·
Apr 23

GenScript leaders await EY Entrepreneur Of The Year New Jersey awards results

Reuters
·
Apr 23

GENSCRIPT BIO (01548) Surges Over 8% in Morning Trading Following Lilly's $70 Billion In Vivo CAR-T Acquisition

Stock News
·
Apr 21

BUZZ-Genscript Biotech climbs as cancer drug CARVYKTI generated $597 mln sales

Reuters
·
Apr 15

GENSCRIPT BIO Reports $597 Million Net Trade Sales for CARVYKTI® in Quarter Ending March 31, 2026

Stock News
·
Apr 14

GenScript announces availability of 2025 ESG report

Reuters
·
Apr 14

Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026

Bulletin Express
·
Apr 14

A Look At GenScript Biotech (SEHK:1548) Valuation After New DNA Data Storage Collaboration With Mimulus

Simply Wall St.
·
Apr 13

GenScript Reports 2025 ESG Progress: 10% Emissions Drop, 58% Female Workforce and SBTi-Aligned Net-Zero Roadmap

Bulletin Express
·
Apr 13

GENSCRIPT BIO Sets 5 June 2026 AGM; Shareholders to Vote on FY-2025 Statements, Director Re-elections and 20% Issuance Mandate

Bulletin Express
·
Apr 13

GenScript Bio to Seek 20% Issuance Headroom, 10% Buy-Back Capacity and Charter Revamp at 5 June 2026 AGM

Bulletin Express
·
Apr 13

GenScript publishes 2025 environmental, social and governance report

Reuters
·
Apr 13

GenScript Biotech announces annual general meeting notice

Reuters
·
Apr 13

金斯瑞生物科技2025年营收大增61.4%至9.60亿美元,受Legend投资减值影响净亏损5.32亿美元

Bulletin Express
·
Apr 13

GenScript Biotech publishes 2025 annual report

Reuters
·
Apr 13

Genscript Bio Plans Fifth Amended Memorandum and Articles to Comply with Updated HKEX Rules

Bulletin Express
·
Apr 10